Provided By GlobeNewswire
Last update: Jul 23, 2025
REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today issued the following letter to shareholders from Chief Executive Officer Gil Efron, highlighting the Company’s scientific progress, operational execution, and strategic milestones during the first half of 2025.
Read more at globenewswire.comNASDAQ:PPBT (8/18/2025, 12:51:20 PM)
2.22
-0.09 (-3.9%)
Find more stocks in the Stock Screener